ArticleVaccine2007
Effects of fungal N- and O-linked mannosylation on the immunogenicity of model vaccines.
Article in Vaccine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 53 citations in OpenAlex.
- Trial
- Structural and Functional Glycosylation of the Abdala COVID-19 Vaccine.Glycobiology · 2025Article
- The Role of Mucoadhesion and Mucopenetration in the Immune Response Induced by Polymer-Based Mucosal Adjuvants.Polymers · 2023Review
- Pichia pastoris: A highly successful expression system for optimal synthesis of heterologous proteins.Journal of cellular physiology · 2020Review
- N-glycosylation converts non-glycoproteins into mannose receptor ligands and reveals antigen-specific T cell responses in vivo.Oncotarget · 2017Article
- Convergent chemo-enzymatic synthesis of mannosylated glycopeptides; targeting of putative vaccine candidates to antigen presenting cells.Chemical science · 2015Article
- Exploiting fungal cell wall components in vaccines.Seminars in immunopathology · 2015Review
- Article
- Engineering yeast for producing human glycoproteins: where are we now?Future microbiology · 2015Article
- Vaccines in the treatment of invasive candidiasis.Virulence · 2015Review
- Vaccine immunity against fungal infections.Current opinion in immunology · 2014Review
- Mannosylated LigANI produced in Pichia pastoris protects hamsters against leptospirosis.Current microbiology · 2014Article
- Anti-Saccharomyces cerevisiae autoantibodies in autoimmune diseases: from bread baking to autoimmunity.Clinical reviews in allergy & immunology · 2013Review
- Mannosylated mucin-type immunoglobulin fusion proteins enhance antigen-specific antibody and T lymphocyte responses.PloS one · 2012Article
- Vaccines for invasive fungal infections.F1000 medicine reports · 2011Article
- Recent advancements in cytotoxic T lymphocyte generation methods using carbohydrate-coated liposomes.Journal of biomedicine & biotechnology · 2010Review
- The mannosylated extracellular domain of Her2/neu produced in P. pastoris induces protective antitumor immunity.BMC cancer · 2009Article
- Role of the mannose receptor in a murine model of Cryptococcus neoformans infection.Infection and immunity · 2008Article
- HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells.PLoS pathogens · 2007Article
- Effect of differential N-linked and O-linked mannosylation on recognition of fungal antigens by dendritic cells.PloS one · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Targeting dendritic cell mannose receptors by mannosylating antigens represents a promising vaccination strategy. Using the model antigen ovalbumin (OVA) expressed recombinantly in bacterial and yeast vectors, we have previously demonstrated fungal mannosylation enhances antigen immunogenicity in the context of CD4(+) T cell responses. However, because protection against many tumors and pathogens is thought to require MHC class I-restricted T cell responses, the capacity of differentially mannosylated OVA antigens to induce antigen-specific CD8(+) T cell proliferation was determined. We found that mannosylated yeast-derived OVA antigens were more potent than their unmannosylated counterparts at inducing antigen-specific T cell proliferation. However, the type of mannosylation was critical as addition of extensive O-linked mannosylation increased lymphoproliferative responses while the presence of N-linked mannosylation was associated with decreased responses. Mannosylated OVA failed to stimulate TNF-alpha and IL-12 production from dendritic cells. These data suggest that vaccines incorporating mannosylation must take into account how the mannose groups are linked to the core antigen and may need to include an adjuvant to stimulate cytokine production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.